Sterling Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Sterling Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$714	Sell	234 -1,329	-85%	-$5.28K	﹤0.01%	3186
2026 Q1	$7.03K	Sell	1,563 -1,239	-44%	-$4.95K	﹤0.01%	2567
2025 Q4	$10.7K	Sell	2,802 -442	-14%	-$1.72K	﹤0.01%	2574
2025 Q3	$10.5K	Buy	3,244 +2,101	+184%	+$7.88K	﹤0.01%	2460
2025 Q2	$3.3K	Buy	1,143 +1,100	+2,558%	+$2.55K	﹤0.01%	2734
2025 Q1	$92	Hold	43	–	–	﹤0.01%	3151
2024 Q4	$166	Hold	43	–	–	﹤0.01%	3137
2024 Q3	$282	Buy	+43	New	+$346	﹤0.01%	3048

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Sterling Capital Management's LRMR Position: Q2 2026 in Review

Sterling Capital Management reduced its Larimar Therapeutics (LRMR) stake by 85% in Q2 2026, selling an estimated $5.28K and leaving 234 shares worth $714. The position accounts for ﹤0.01% of the portfolio, ranked #3186.

Sterling Capital Management first reported a position in LRMR in Q3 2024 and has held it in 8 quarters since. The position peaked at $10.7K in Q4 2025. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

Sterling Capital Management held 234 shares of Larimar Therapeutics worth $714 as of Q2 2026.
Sterling Capital Management sold 1,329 Larimar Therapeutics shares in Q2 2026, an estimated $5.28K.
Larimar Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3186 holding.
Sterling Capital Management first reported a position in Larimar Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Larimar Therapeutics position peaked at $10.7K in Q4 2025.
163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.